MX2016015856A - Derivados de naftiridinadiona. - Google Patents

Derivados de naftiridinadiona.

Info

Publication number
MX2016015856A
MX2016015856A MX2016015856A MX2016015856A MX2016015856A MX 2016015856 A MX2016015856 A MX 2016015856A MX 2016015856 A MX2016015856 A MX 2016015856A MX 2016015856 A MX2016015856 A MX 2016015856A MX 2016015856 A MX2016015856 A MX 2016015856A
Authority
MX
Mexico
Prior art keywords
naphthyridinedione
derivatives
naphthyridinedione derivatives
medicaments
medicament
Prior art date
Application number
MX2016015856A
Other languages
English (en)
Inventor
Reinhardt Juergen
Schmiedeberg Niko
Spanka Carsten
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016015856A publication Critical patent/MX2016015856A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un compuesto de la fórmula (I'): (Ver Fórmula) o a una sal del mismo, en donde los sustituyentes son como se definen en la memoria descriptiva; a su preparación, a su uso como un medicamento, y a los medicamentos que lo comprenden.
MX2016015856A 2014-06-03 2015-06-02 Derivados de naftiridinadiona. MX2016015856A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14170976 2014-06-03
PCT/IB2015/054174 WO2015186063A1 (en) 2014-06-03 2015-06-02 Naphthyridinedione derivatives

Publications (1)

Publication Number Publication Date
MX2016015856A true MX2016015856A (es) 2017-04-25

Family

ID=50841689

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015856A MX2016015856A (es) 2014-06-03 2015-06-02 Derivados de naftiridinadiona.

Country Status (28)

Country Link
US (2) US10138232B2 (es)
EP (1) EP3152209B1 (es)
JP (2) JP6343034B2 (es)
KR (1) KR101905295B1 (es)
CN (1) CN106459043B (es)
AP (1) AP2016009545A0 (es)
AR (1) AR100706A1 (es)
AU (2) AU2015270125B2 (es)
BR (1) BR112016027383A8 (es)
CA (1) CA2950724A1 (es)
CL (1) CL2016003081A1 (es)
CR (1) CR20160565A (es)
CU (1) CU24438B1 (es)
EA (1) EA030374B1 (es)
EC (1) ECSP16096831A (es)
ES (1) ES2731802T3 (es)
GT (1) GT201600252A (es)
IL (1) IL248773B (es)
MX (1) MX2016015856A (es)
MY (1) MY178379A (es)
PE (1) PE20170086A1 (es)
PH (2) PH12016502293A1 (es)
SG (1) SG11201609209YA (es)
SV (1) SV2016005331A (es)
TN (1) TN2016000490A1 (es)
TW (1) TWI688565B (es)
UY (1) UY36150A (es)
WO (1) WO2015186063A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000490A1 (en) 2014-06-03 2018-04-04 Novartis Ag Naphthyridinedione derivatives.
US9884862B2 (en) 2014-06-03 2018-02-06 Novartis Ag Pyridopyrimidinedione derivatives
US9896448B2 (en) 2014-06-03 2018-02-20 Novartis Ag Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2020022375A1 (ja) 2018-07-24 2020-01-30 ソニーセミコンダクタソリューションズ株式会社 半導体装置
WO2024161623A1 (ja) * 2023-02-03 2024-08-08 株式会社 RINAT Imaging リードスルー薬、リードスルー用組み合わせ剤及び核酸プローブの使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ ５−デアザフラビン系化合物を有効成分とする制癌剤
JP2989871B2 (ja) * 1989-08-30 1999-12-13 大日本製薬株式会社 三環式化合物
DE4035479A1 (de) 1990-11-08 1992-05-14 Basf Ag Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6016875A (en) * 1998-02-10 2000-01-25 Case Corporation Gain adaptation control for hydraulic systems
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
HUE055434T2 (hu) 2003-04-11 2021-11-29 Ptc Therapeutics Inc 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PT2502911T (pt) 2004-06-24 2017-07-10 Vertex Pharma Moduladores de transportadores de cassete de ligação de atp
CN101076332A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 吡唑或三唑化合物及其用于制备治疗体细胞突变相关疾病的药物的用途
CA2646407C (en) 2006-04-03 2015-08-18 Technion Research & Development Foundation Ltd. Novel aminoglycosides and uses thereof in the treatment of genetic disorders
US20080090845A1 (en) 2006-08-23 2008-04-17 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
HUE025553T2 (en) * 2007-05-25 2016-02-29 Vertex Pharma CFTR modulators
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
ES2710854T3 (es) * 2010-08-05 2019-04-29 Univ Lille Compuesto útil para el tratamiento de enfermedades mediadas por una mutación sin sentido y composición farmacéutica que comprende dicho compuesto
SG11201503684WA (en) 2012-12-13 2015-06-29 Novartis Ag Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
US9884862B2 (en) 2014-06-03 2018-02-06 Novartis Ag Pyridopyrimidinedione derivatives
US9896448B2 (en) 2014-06-03 2018-02-20 Novartis Ag Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
TN2016000490A1 (en) 2014-06-03 2018-04-04 Novartis Ag Naphthyridinedione derivatives.

Also Published As

Publication number Publication date
ECSP16096831A (es) 2018-04-30
AP2016009545A0 (en) 2016-11-30
JP2017516821A (ja) 2017-06-22
WO2015186063A1 (en) 2015-12-10
MY178379A (en) 2020-10-09
GT201600252A (es) 2018-12-18
BR112016027383A2 (pt) 2017-08-15
CU24438B1 (es) 2019-09-04
EP3152209A1 (en) 2017-04-12
AR100706A1 (es) 2016-10-26
CN106459043B (zh) 2018-12-28
AU2015270125A1 (en) 2016-11-24
UY36150A (es) 2016-01-29
CA2950724A1 (en) 2015-12-10
AU2018200421A1 (en) 2018-02-08
IL248773B (en) 2019-12-31
PH12016502293B1 (en) 2017-02-13
AU2015270125B2 (en) 2017-10-19
US10138232B2 (en) 2018-11-27
JP6343034B2 (ja) 2018-06-13
SG11201609209YA (en) 2016-12-29
EA201692270A1 (ru) 2017-03-31
CN106459043A (zh) 2017-02-22
TW201625610A (zh) 2016-07-16
BR112016027383A8 (pt) 2021-07-20
PH12016502293A1 (en) 2017-02-13
EA030374B1 (ru) 2018-07-31
US20150344476A1 (en) 2015-12-03
TWI688565B (zh) 2020-03-21
CL2016003081A1 (es) 2017-06-09
US20190248784A1 (en) 2019-08-15
CR20160565A (es) 2017-03-10
CU20160182A7 (es) 2017-03-03
KR20160148679A (ko) 2016-12-26
EP3152209B1 (en) 2019-03-20
PH12018501709A1 (en) 2019-08-14
PE20170086A1 (es) 2017-03-17
IL248773A0 (en) 2017-01-31
ES2731802T3 (es) 2019-11-19
TN2016000490A1 (en) 2018-04-04
JP2018138609A (ja) 2018-09-06
KR101905295B1 (ko) 2018-10-05
SV2016005331A (es) 2018-08-20

Similar Documents

Publication Publication Date Title
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12018501709A1 (en) Naphthridinedione derivatives
MX2017014035A (es) Formas solidas novedosas.
EP4356736A3 (en) Synthesis of boronate salts
IN2015DN03998A (es)
PH12016501462A1 (en) Neprilysin inhibitors
TW201613864A (en) Novel compounds
MY181641A (en) Amino pyran ring derivative and composition and use thereof
IN2014DN10449A (es)
NZ746317A (en) Aminothiazole derivatives useful as antiviral agents
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
MX370598B (es) Fenoxiacetamidas apareadas novedosas.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia

Legal Events

Date Code Title Description
FG Grant or registration